Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.76 |
| ▸ | RAB9A | P51151 | 9/20 | 0.74 |
| ▸ | NPC1 | O15118 | 5/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | ESRRG | P62508 | 1/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27177974 | 1.00 | GAA (0.76) | GAARAB9ANPC1KMT2AMEN1 | |
| SCHEMBL30826051 | 1.00 | GAA (0.76) | GAARAB9ANPC1KMT2AMEN1 | |
| SCHEMBL27178276 | 0.88 | GAA (0.86) | GAARAB9ANPC1KMT2AMEN1 | |
| SCHEMBL27178272 | 0.88 | GAA (0.86) | GAARAB9ANPC1KMT2AMEN1 | |
| SCHEMBL30826124 | 0.86 | GAA (0.80) | GAARAB9ANPC1KMT2AMEN1 | |
| SCHEMBL27178006 | 0.86 | GAA (0.80) | GAARAB9ANPC1KMT2AMEN1 | |
| SCHEMBL27178001 | 0.86 | GAA (0.80) | GAARAB9ANPC1KMT2AMEN1 | |
| SCHEMBL10805111 | 0.85 | RAB9A (1.00) | GAARAB9ANPC1KMT2AMEN1 | |
| SCHEMBL30826099 | 0.83 | RAB9A (1.00) | GAARAB9ANPC1KMT2AMEN1 | |
| SCHEMBL27177931 | 0.83 | RAB9A (1.00) | GAARAB9ANPC1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4580403-A2 | APYRASE INHIBITORS | Texas Crop Science, Inc. (US) | 2025-07-09 | — | — | EP | claimed |
| US-20240101510-A1 | APYRASE INHIBITORS | TEXAS CROP SCIENCE, INC. | 2024-03-28 | — | — | US | claimed |
| WO-2024050040-A2 | APYRASE INHIBITORS | TEXAS CROP SCIENCE (US) | 2024-03-07 | — | — | WO | claimed |
| US-5011932-A | Anthelmintic pyridinyl acylhydrazones derivatives | UPJOHN COMPANY (US) | 1991-04-30 | — | — | US | claimed |
| US-20240101510-A1 | APYRASE INHIBITORS | TEXAS CROP SCIENCE, INC. | 2024-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101510-A1 | APYRASE INHIBITORS | APEH, DPEP1, PON1 | GAA 168/4885RAB9A 1387/4885NPC1 2564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.